Nearly 85 % of lung-cancer-specific EGFR mutations comprise a leucine-to-arginine substitution at position 858 (21L858R) and a deletion mutation in exon 19 that affects the conserved sequence LREA (19del) (Rosell et al. 2009). This evidence concerns the gene EGFR and lung carcinoma.